Innate Pharma S.A.·Healthcare

MARSEILLE, France--(BUSINESS WIRE)-- #AACR--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), announced today that Yannis Morel, Chief Operating Officer, will present at the AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients. Yannis Morel will present in the Showcase Session 2 on Thursday, April 16, 2026, at 6:10 PM PDT, at the San Diego Convention Center in San Diego, California. The AACR Oncology Industry Partnering Event is a.

MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the Kempen Life Sciences conference.

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma Files Its 2025 Universal Registration Document (Document D'enregistrement Universel) And 2025 Form 20-f Annual Report.

Innate Pharma (NASDAQ: IPHA) outlined progress across its prioritized oncology pipeline and reviewed full-year 2025 financial results, emphasizing a streamlined strategy centered on three clinical programs: lacutamab, IPH4502, and monalizumab. Management also highlighted an AstraZeneca-partnered program, IPH5201, with upcoming interim data to be presented at a major medical meeting. Strategy refocus and organizational streamlining Chief Executive

Innate Pharma S.A. (IPHA) Q4 2025 Earnings Call Transcript

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its business update and consolidated financial results for the year ending December 31, 2025. The consolidated financial statements are attached to this press release. “2025 has been a year of strong execution across our portfolio. With the TELLOMAK-3 design finalized and FDA clearance in hand, lacutamab is planned for confirmatory Phase 3 initiati.
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Healthcare
Biotechnology
181
2019-10-17
0.74